Systemic Lupus Erythematous SLE Drugs Market Segments and Forecast By End-use Industry 2015-2025
Future Market Insights has announced the addition of the “Systemic Lupus Erythematous SLE Drugs Market: Global Industry Analysis and Opportunity Assessment 2015-2025” report to their offering. Future Market Insights has announced the addition of the “Systemic Lupus Erythematous SLE Drugs Market: Global Industry Analysis and Opportunity Assessment 2015-2025” report to their offering.
Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends. We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC. Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and Retail. We have a global presence with delivery centers across India specializing in providing global research reports and country research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India. We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for our client. Research Capabilities • Customized Research • Syndicated Research • Investment Research • Social Media Research Sector Coverage • Automotive and Transportation • Electronics, Semiconductor, and ICT • Retail and Consumer Products • Industrial Automation and Equipment • Chemicals & Materials • Food and Beverages • Services and Utilities • Energy, Mining, Oil, and Gas Customized Research Syndicated Research Investment Research Social Media Research Subscription Information For detailed subscription information please contact Hari. T (Sr. Manager - Global Business Development) T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268 Email: hari.t@futuremarketinsights.com
Report Description Systemic Lupus Erythematous (SLE) is a chronic autoimmune disease which causes the immune system to mistakenly attack health body tissue. In SLE, body immune system can affect any part of the body, such as joints, organs, eyes, skin, etc. Often SLE can result in symptoms such as malar rash, discoid lesions, sub-acute cutaneous lesions, photosensitivity, oral ulcers, arthritis, serositis, nephropathy, neurologic involvement, thrombocytopenia, haemolytic anemia, fever, Raynaud’s phenomenon, livedo reticularis, thrombosis, and myositis. It is also known as a disease of flare-ups and remissions and can range from mild to life threatening severity. It is also called as drug-induced lupus erythematosus due to common observation against drugs such as isoniazid, hydralazine and procainamide. Currently, there is no complete treatment for SLE. While only two biologic agents have been approved by FDA to treat SLE, synthetic drugs are still the mainstay of therapy in SLE. Based on available evidence, azathioprine and mycophenolate mofetil are the drugs of first choice. Hydroxychloroquine should be considered an anchor drug in SLE because of the multiple beneficial effects of this agent. Systemic Lupus Erythematous (SLE) Drugs Market: Drivers & Restraints Global Systemic Lupus Erythematous (SLE) Drugs market is projected to grow due to high prevalence of autoimmune diseases particularly systemic lupus erythematous (SLE). Major drivers for global systemic erythematous drugs market are development of novel SLE therapies, increasing availability of bio similar drugs and increasing support for emerging research areas for new drug molecules. At the same time, increasing awareness of disease diagnosis and treatment as well as consistent research and development processes for novel drug molecules are important drivers for global lupus erythematous market.
- Page 1: Global Systemic Lupus Erythematous
- Page 5 and 6: Report Description •Non-Steroidal
- Page 7 and 8: Report Description Recently, a drug
Report Description<br />
<strong>Systemic</strong> <strong>Lupus</strong> <strong>Erythematous</strong> (<strong>SLE</strong>) is a chronic autoimmune disease which ca<strong>use</strong>s the immune<br />
system to mistakenly attack health body tissue. In <strong>SLE</strong>, body immune system can affect any part<br />
of the body, such as joints, organs, eyes, skin, etc. Often <strong>SLE</strong> can result in symptoms such as<br />
malar rash, discoid lesions, sub-acute cutaneous lesions, photosensitivity, oral ulcers, arthritis,<br />
serositis, nephropathy, neurologic involvement, thrombocytopenia, haemolytic anemia, fever,<br />
Raynaud’s phenomenon, livedo reticularis, thrombosis, <strong>and</strong> myositis. It is also known as a<br />
disease of flare-ups <strong>and</strong> remissions <strong>and</strong> can range from mild to life threatening severity. It is also<br />
called as drug-induced lupus erythematosus due to common observation against drugs such as<br />
isoniazid, hydralazine <strong>and</strong> procainamide. Currently, there is no complete treatment for <strong>SLE</strong>.<br />
While only two biologic agents have been approved by FDA to treat <strong>SLE</strong>, synthetic drugs are still<br />
the mainstay of therapy in <strong>SLE</strong>. Based on available evidence, azathioprine <strong>and</strong> mycophenolate<br />
mofetil are the drugs of first choice. Hydroxychloroquine should be considered an anchor drug<br />
in <strong>SLE</strong> beca<strong>use</strong> of the multiple beneficial effects of this agent.<br />
<strong>Systemic</strong> <strong>Lupus</strong> <strong>Erythematous</strong> (<strong>SLE</strong>) <strong>Drugs</strong> <strong>Market</strong>: Drivers & Restraints<br />
Global <strong>Systemic</strong> <strong>Lupus</strong> <strong>Erythematous</strong> (<strong>SLE</strong>) <strong>Drugs</strong> market is projected to grow due to high<br />
prevalence of autoimmune diseases particularly systemic lupus erythematous (<strong>SLE</strong>). Major<br />
drivers for global systemic erythematous drugs market are development of novel <strong>SLE</strong> therapies,<br />
increasing availability of bio similar drugs <strong>and</strong> increasing support for emerging research areas for<br />
new drug molecules. At the same time, increasing awareness of disease diagnosis <strong>and</strong> treatment<br />
as well as consistent research <strong>and</strong> development processes for novel drug molecules are<br />
important drivers for global lupus erythematous market.
Change language